NIH To Study Nirmatrelvir-Ritonavir In Patients With Long COVID
October 28, 2022
Reuters (10/27, Steenhuysen) reports “the U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc’s antiviral drug” nirmatrelvir-ritonavir (Paxlovid) “as the first treatment it will study in patients with long COVID, organ...